On this page
Short QT syndrome
This syndrome can cause rapid, irregular heartbeats and increases the risk of sudden cardiac arrest, often affecting individuals from birth, though symptoms may only appear later in life. It is typically passed down through families.
Overview
Short QT syndrome (SQTS) is a very rare inherited heart condition that affects the heart's electrical system. Normally, after each heartbeat, the heart muscle cells need a specific amount of time to 'recharge' before the next beat; this process is called repolarisation. In SQTS, this repolarisation happens much faster than usual, leading to a shorter-than-normal QT interval on an electrocardiogram (ECG) [PMID:33678567].
This accelerated repolarisation can make the heart more susceptible to developing dangerously fast and disorganised heart rhythms, known as arrhythmias. These arrhythmias can lead to symptoms such as palpitations, fainting (syncope), or, in severe cases, sudden cardiac arrest. Because it is an inherited condition, SQTS can affect multiple members within the same family.
While SQTS is present from birth, symptoms may not appear until later in childhood or adulthood. The exact prevalence of SQTS is not well established, but it is considered to be a very rare condition. Awareness and early diagnosis are important for managing the condition and reducing associated risks.
Symptoms & clinical features
The symptoms of Short QT syndrome can vary significantly among affected individuals, even within the same family. Some people may experience no symptoms at all and only be diagnosed after an ECG is performed for another reason, or if a family member is diagnosed. Others may have more noticeable symptoms related to the heart's electrical instability.
Common symptoms can include palpitations, which are sensations of a racing, pounding, or fluttering heart. Individuals may also experience syncope, which is a sudden loss of consciousness or fainting spell. This often occurs when the heart's electrical system becomes disorganised, leading to a temporary drop in blood supply to the brain. In some instances, SQTS can tragically manifest as sudden cardiac arrest, where the heart suddenly stops beating effectively [PMID:33678567].
Symptoms may be triggered by factors such as exercise, fever, or emotional stress, although they can also occur at rest. It is important for anyone experiencing such symptoms to seek medical attention promptly for proper evaluation and diagnosis.
Video: Genetics 101
Affected organs
Short QT syndrome primarily affects the heart, specifically its electrical system. The heart's function relies on a precise sequence of electrical signals that coordinate the contraction and relaxation of its chambers. In SQTS, the channels responsible for controlling the flow of ions (like potassium) across heart cell membranes are altered, leading to a disturbance in this electrical activity.
The most significant impact is on the ventricular repolarisation phase, which is the 'recharging' period of the heart's main pumping chambers. This shortened repolarisation makes the heart more vulnerable to developing life-threatening arrhythmias. While the structural integrity of the heart muscle is typically normal in SQTS, the electrical dysfunction can have severe consequences.
Risks & severity
The severity of Short QT syndrome can range from asymptomatic individuals to those at high risk of life-threatening events. The primary and most serious risk associated with SQTS is sudden cardiac arrest and sudden cardiac death [PMID:33678567]. This risk is present throughout an affected individual's life, though it can vary. While specific lifetime risk percentages are not precisely defined due to the condition's rarity, the potential for serious outcomes underscores the importance of diagnosis and management.
Symptoms can emerge at any age, from infancy to adulthood. Some individuals may experience their first symptoms during childhood or adolescence, while others may remain asymptomatic until later in life, or even never develop symptoms. The presence of symptoms such as syncope or a history of sudden cardiac arrest in a family member typically indicates a higher risk profile. Identifying affected individuals and those at risk is crucial for implementing appropriate surveillance and preventative measures.
Genetic causes
Short QT syndrome is caused by pathogenic variants in specific genes that control the function of ion channels in heart cells. These channels are responsible for the flow of electrical currents that regulate the heart's rhythm. When these genes have a pathogenic variant, the ion channels can malfunction, leading to the characteristic shortened repolarisation time.
Several genes have been identified as causative for SQTS, including KCNH2, KCNJ2, and KCNQ1. For example, KCNH2 encodes a key component of the hERG potassium channel, which is vital for the heart's repolarisation phase [PMID:16531602]. Pathogenic changes in KCNH2 can lead to an overactive channel or altered channel kinetics, accelerating repolarisation. Similarly, KCNJ2 and KCNQ1 also encode potassium channel proteins that are crucial for maintaining the heart's normal electrical activity.
Pathogenic variants in these genes typically lead to an increase in potassium current or a decrease in calcium current, both of which shorten the QT interval. Understanding the specific genetic cause can sometimes help inform management strategies and identify other at-risk family members.
- KCNH2 potassium voltage-gated channel subfamily H member 2The KCNH2 gene provides instructions for making a potassium channel protein crucial for regulating the electrical activity of heart muscle cells, maintaining a regular heart rhythm.
- KCNJ2 potassium inwardly rectifying channel subfamily J member 2
- KCNQ1 potassium voltage-gated channel subfamily Q member 1The KCNQ1 gene provides instructions for making a protein that forms a critical part of voltage-gated potassium channels, which are essential for regulating electrical signals in the heart and inner ear.
Inheritance pattern
Short QT syndrome is typically inherited in an autosomal dominant pattern. This means that a person only needs to inherit one copy of a pathogenic gene variant from either parent to develop the condition. If one parent has SQTS, there is a 50% chance with each pregnancy that their child will inherit the pathogenic variant and therefore the condition.
Autosomal dominant inheritance patterns mean that the condition can affect males and females equally. It also implies that if a person has the condition, one of their parents typically also has it, although sometimes the pathogenic variant can arise new (de novo) in an individual, meaning neither parent carries the variant. Genetic counselling is often recommended for affected individuals and their families to understand the inheritance pattern and the implications for family planning and cascade screening.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosing Short QT syndrome usually begins with a thorough clinical evaluation, including a review of personal and family medical history. A key diagnostic tool is the electrocardiogram (ECG), which measures the heart's electrical activity. A shortened QT interval on an ECG, especially when corrected for heart rate (QTc), is the hallmark of SQTS [PMID:33678567]. However, the exact cut-off for a 'short' QT interval can vary slightly, and clinical judgement is important.
Further investigations may include Holter monitoring (a portable ECG that records heart activity over 24-48 hours), exercise stress tests, and sometimes electrophysiological studies. Once clinical suspicion is high, genetic testing is often recommended to identify a pathogenic variant in one of the associated genes (e.g., KCNH2, KCNJ2, KCNQ1) [PMID:16531602]. Genetic testing can confirm the diagnosis and help with cascade screening of family members. Within the NHS Genomic Medicine Service, genetic testing for inherited cardiac conditions, including SQTS, falls under specific R-codes (e.g., R140 - Inherited arrhythmia syndromes) and is typically coordinated by clinical geneticists or specialist cardiologists.
Management & lifestyle
The management of Short QT syndrome focuses on reducing the risk of life-threatening arrhythmias and sudden cardiac arrest. Given the rarity of the condition, management strategies are often tailored to the individual's symptoms, ECG findings, and genetic variant. Medications, such as quinidine, may be prescribed to help prolong the QT interval and reduce the risk of arrhythmias, although more research is ongoing to fully understand their long-term effectiveness in all individuals with SQTS.
For individuals considered to be at high risk, particularly those who have experienced symptoms like syncope or a previous cardiac arrest, an implantable cardioverter-defibrillator (ICD) may be recommended. An ICD is a small device surgically placed in the chest that can monitor heart rhythm and deliver an electrical shock to restore a normal rhythm if a dangerous arrhythmia occurs. Regular follow-up with a cardiologist specialising in inherited cardiac conditions is essential to monitor the condition and adjust management as needed.
Patients are typically advised to avoid certain medications that can further shorten the QT interval or trigger arrhythmias. Lifestyle modifications, such as avoiding excessive caffeine or strenuous exercise for some individuals, may also be considered in discussion with their medical team. Genetic counselling plays a crucial role in providing support and information regarding the condition and its implications for family members.
UK care pathway
In the UK, individuals suspected of having Short QT syndrome are typically referred to specialist NHS services, often within inherited cardiac conditions clinics. These clinics are usually led by cardiologists with expertise in genetic heart conditions, working alongside clinical geneticists and genetic counsellors. Diagnosis and genetic testing for inherited arrhythmia syndromes, including SQTS, are offered through the NHS Genomic Medicine Service (GMS) pathways. Genetic testing typically falls under specific R-codes, such as R140 for inherited arrhythmia syndromes, facilitating comprehensive genomic analysis.
Following diagnosis, a multidisciplinary team will develop a personalised management plan. Genetic counsellors provide vital support, helping individuals and families understand the inheritance pattern, implications for other family members, and options for cascade screening. The aim is to provide ongoing surveillance and appropriate interventions to minimise risks associated with the condition.
Frequently asked questions
What does a 'short QT interval' mean on an ECG?
A short QT interval on an ECG means that the heart's electrical 'recharging' phase happens faster than normal. This can make the heart more prone to developing fast and dangerous irregular heart rhythms, increasing the risk of symptoms like fainting or sudden cardiac arrest.
Is Short QT syndrome always passed down from parents?
Short QT syndrome is typically an inherited condition, usually passed down in an autosomal dominant pattern. This means if one parent has the condition, each child has a 50% chance of inheriting it. However, sometimes the genetic change can occur spontaneously in a person, meaning neither parent carries the variant.
Can Short QT syndrome be cured?
There is currently no cure for Short QT syndrome, but it can be managed. Treatment focuses on reducing the risk of dangerous heart rhythms through medications or, in high-risk cases, an implantable cardioverter-defibrillator (ICD). Regular monitoring and lifestyle adjustments are also part of managing the condition.
If I have Short QT syndrome, should my family members be tested?
Yes, if you are diagnosed with Short QT syndrome, it is generally recommended that your close family members (parents, siblings, children) consider genetic testing and cardiac screening. This is known as cascade screening and helps identify other at-risk individuals who may benefit from monitoring and management.
What activities should I avoid if I have Short QT syndrome?
Specific recommendations vary for each individual and should be discussed with your cardiologist. In some cases, individuals with Short QT syndrome may be advised to avoid strenuous exercise, certain medications that affect heart rhythm, or excessive caffeine. Your medical team will provide personalised advice based on your symptoms and risk factors.
References
- Brugada R, Hong K, Cordeiro JM. Short QT syndrome. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2005. PMID: 16301704
- Schimpf R, Wolpert C, Gaita F. Short QT syndrome. Cardiovascular research. 2005. PMID: 15890322
- Dib Nehme R, Sinno L, Shouman W. Cardiac Channelopathies: Clinical Diagnosis and Promising Therapeutics. Journal of the American Heart Association. 2025. PMID: 40281647
- Schwartz PJ, Ackerman MJ, Antzelevitch C. Inherited cardiac arrhythmias. Nature reviews. Disease primers. 2020. PMID: 32678103
- Kim JB. Channelopathies. Korean journal of pediatrics. 2014. PMID: 24578711
- Bjerregaard P, Gussak I. Short QT syndrome. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc. 2005. PMID: 16255754
- Sanguinetti MC. HERG1 channelopathies. Pflugers Archiv : European journal of physiology. 2010. PMID: 20544339
- Roberti R, De Caro C, Iannone LF. Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability. CNS drugs. 2021. PMID: 33993416